These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29721050)

  • 1. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
    Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
    J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
    [No Abstract]   [Full Text] [Related]  

  • 2. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
    Xiu P; Xu Z; Liu F; Li Z; Li T; Zou F; Sun X; Li J
    Dig Dis Sci; 2014 Aug; 59(8):1798-809. PubMed ID: 24671452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
    Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
    Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
    Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
    J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
    Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
    Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
    Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
    Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic role of meloxicam targeting secretory clusterin-mediated invasion in hepatocellular carcinoma cells.
    Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
    Oncol Lett; 2018 May; 15(5):7191-7199. PubMed ID: 29731881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target.
    Zheng W; Yao M; Qian Q; Sai W; Qiu L; Yang J; Wu W; Dong Z; Yao D
    Oncotarget; 2017 Aug; 8(32):52321-52332. PubMed ID: 28881732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin.
    Ma X; Bai Y
    Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells.
    Yan Y; Luo K; Zhang H; Chai W
    Hepatogastroenterology; 2013; 60(121):70-5. PubMed ID: 22975582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
    Narahara S; Watanabe T; Nagaoka K; Fujimoto N; Furuta Y; Tanaka K; Tokunaga T; Kawasaki T; Yoshimaru Y; Setoyama H; Oniki K; Saruwatari J; Tateyama M; Naoe H; Tanaka M; Tanaka Y; Sasaki Y
    Hepatol Commun; 2022 May; 6(5):1198-1212. PubMed ID: 34837478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
    Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
    Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
    Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
    Zhang J; Wu M; Xu Y; Song Q; Zheng W
    Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma.
    Zheng W; Yao M; Sai W; Qian Q; Pan L; Qiu L; Huang J; Wu W; Yao D
    Tumour Biol; 2016 Jan; 37(1):999-1008. PubMed ID: 26264614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.
    Ye JZ; Yan SM; Yuan CL; Wu HN; Zhang JY; Liu ZH; Li YQ; Luo XL; Lin Y; Liang R
    J Cancer; 2018; 9(2):415-423. PubMed ID: 29344288
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of secretory clusterin in hepatocarcinogenesis.
    Yao M; Fang M; Zheng W; Dong Z; Yao D
    Transl Gastroenterol Hepatol; 2018; 3():48. PubMed ID: 30221206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
    Zhang B; Liu ZM; Hao FG; Wang M
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.
    Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D
    Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
    Ma G; Cai H; Gao L; Wang M; Wang H
    World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.